Breast Cancer Liquid Biopsy Market to reach $1.7 Billion by 2030; the escalating incidence of breast cancer combined with the limitations and invasiveness of traditional diagnostic methods drives the need for Breast Cancer Liquid Biopsy

The Breast Cancer Liquid Biopsy Market size is estimated to reach $1.7 Billion by 2030, growing at a CAGR of 21.8% during the forecast period 2024-2030, according to a recent report published by IndustryARC, titled, “ Breast Cancer Liquid Biopsy – By Circulating Biomarkers (- Circulating Tumor Cells (CTCs) , Cell-free DNA (cfDNA), Cell- Free RNA (cfRNA), Circulating Tumor DNA (ctDNA), Circulating Tumor RNA (ctRNA), Extracellular Vesicles(EVs) and Other Biomakers) , By Product (Consumables, Instruments and Services), By Application (Early Detection, Therapy Selection, Treatment Monitoring and Recurrence Monitoring), By End User (Research Institutes, Public Health Laboratories , Hospitals, Molecular Laboratories, Pathology Laboratories and Others), and By Geography Global Opportunity Analysis & Industry Forecast, 2024-2030.”

The growing demand for non-invasive procedures drives the expansion of the Breast Cancer Liquid Biopsy industry. Advancements in technological capabilities also contribute to this growth. Additionally, increased breast cancer awareness programs are fueling the industry's development during the forecast period.

North America accounted for the largest share of 42% of the Breast Cancer Liquid Biopsy Market in 2023. The robust healthcare infrastructure, early adoption of innovative technologies such as Liquid Biopsy, substantial research investments and favourable regulatory environment propels the demand for Breast Cancer Liquid Biopsy. As per Breast Cancer Research Foundation (BCRF), there are more than 4 million breast cancer survivors in the United States, including women still being treated and those who have completed treatment.  In January 2023, the U.S. Food and Drug Administration (FDA) approved several new liquid biopsy tests, including the Guardant360 CDx blood-based liquid biopsy for detecting and monitoring breast cancer. Such developments highlight the advances in breast cancer detection, treatment, and survivorship with the favorable regulatory environment in North America reflecting the progress made in oncology and the importance of continued support and innovation in breast cancer care.

According to the World Health Organization (WHO), breast cancer is the most frequent type of cancer among women across the globe. Approximately 2.1 million women suffer from breast cancer every year and it leads to the highest number of cancer-related deaths among women. As the number of new breast cancer cases continues to rise, there is a corresponding increase in demand for early detection, monitoring, and treatment options increases, driving the adoption of liquid biopsy as a valuable tool. Liquid biopsy, with its non-invasive nature and potential for early detection, has emerged as a promising tool to address the challenges posed by breast cancer and can play a pivotal role in improving overall patient outcomes and addressing the growing burden of these conditions.

Traditional methods like mammograms and tissue biopsies often involve invasive procedures that can cause discomfort and anxiety. Liquid biopsy offers a less invasive alternative by analyzing circulating biomarkers such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in blood samples. This approach enables earlier detection, real-time monitoring of disease progression and personalized treatment plans. This approach offers a significant advantage over traditional invasive methods by providing a dynamic view of tumor progression without subjecting patients to the risks and discomfort associated with tissue biopsies.

Key companies profiled in the Breast Cancer Liquid Biopsy Market are Qiagen, Thermo Fisher Scientific, Bio-Rad Laboratories Inc., Guardant Health Inc, Neo Genomics Laboratories, F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc, Angle PLC, Sysmex Corporation, Illumina Inc. and others.

Breast Biopsy Devices Market– Breast Biopsy Devices Market Size is projected to reach $3.4 Billion by 2030, after growing at a CAGR of 5.1% during the forecast period 2024-2030. Advancements in medical technology, rising incidence of breast cancer, and increasing awareness about early detection are driving the market growth.

Cancer Testing Screening Market – Cancer Testing Screening Market size is projected to reach $220.66 billion by 2027 and is expected to grow at a CAGR of 6.4% during the forecast period 2022-2027, owing to its usage for aid in the early detection of cancer before symptoms occur, particularly in countries with the highest cancer rates.

Cancer Diagnostics Market - The Cancer Diagnostics Market size is estimated to reach $241.7 billion by 2027, growing at a CAGR of 6.3% during the forecast period 2022-2027. The expanding population of the elderly requiring magnetic resonance imaging along with the augmenting collaborative and independent actions directed by governments and are set to propel the growth of the Cancer Diagnostics Industry.